Ionis Pharmaceuticals Inc stock is traded at $38.80, with a volume of 2,970,416. It is down -3.36% in the last 24 hours and down -10.80% over the past month. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Previous Close:
$40.15
Open:
$40.31
24h Volume:
2,970,416
Relative Volume:
1.09
Market Cap:
$6.45B
Revenue:
$1.06B
Net Income/Loss:
-$326.58M
P/E Ratio:
-
EPS:
-$2.10
Net Cash Flow:
-$977.73M
1W Performance:
-12.59%
1M Performance:
-10.80%
6M Performance:
-48.44%
1Y Performance:
-48.04%
1-Day Range:
$38.31$40.50
1-Week Range:
$38.31$43.91
52-Week Range:
$38.31$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
(760) 931-9200Address
2855 GAZELLE COURT, CARLSBAD, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS